Literature DB >> 18852132

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Roberto R Rosato1, Jorge A Almenara, Sonia C Maggio, Stefanie Coe, Peter Atadja, Paul Dent, Steven Grant.   

Abstract

The role of reactive oxygen species (ROS) production on DNA damage and potentiation of fludarabine lethality by the histone deacetylase inhibitor (HDACI) LAQ-824 was investigated in human leukemia cells. Preexposure (24 h) of U937, HL-60, Jurkat, or K562 cells to LAQ-824 (40 nmol/L) followed by fludarabine (0.4 micromol/L) dramatically potentiated apoptosis (>or=75%). LAQ-824 triggered an early ROS peak (30 min-3 h), which declined by 6 h, following LAQ-824-induced manganese superoxide dismutase 2 (Mn-SOD2) upregulation. LAQ-824/fludarabine lethality was significantly diminished by either ROS scavengers N-acetylcysteine or manganese (III) tetrakis (4-benzoic acid) porphyrin or ectopic Mn-SOD2 expression and conversely increased by Mn-SOD2 antisense knockdown. During this interval, LAQ-824 induced early (4-8 h) increases in gamma-H2AX, which persisted (48 h) secondary to LAQ-824-mediated inhibition of DNA repair (e.g., down-regulation of Ku86 and Rad50, increased Ku70 acetylation, diminished Ku70 and Ku86 DNA-binding activity, and down-regulated DNA repair genes BRCA1, CHEK1, and RAD51). Addition of fludarabine further potentiated DNA damage, which was incompatible with cell survival, and triggered multiple proapoptotic signals including activation of nuclear caspase-2 and release of histone H1.2 into the cytoplasm. The latter event induced activation of Bak and culminated in pronounced mitochondrial injury and apoptosis. These findings provide a mechanistic basis for understanding the role of early HDACI-induced ROS generation and modulation of DNA repair processes in potentiation of nucleoside analogue-mediated DNA damage and lethality in leukemia. Moreover, they show for the first time the link between HDACI-mediated ROS generation and the recently reported DNA damage observed in cells exposed to these agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852132      PMCID: PMC2586957          DOI: 10.1158/1535-7163.MCT-08-0385

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  51 in total

1.  The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

Authors:  Roberto R Rosato; Jorge A Almenara; Leanne Cartee; Vicki Betts; Srikumar P Chellappan; Steven Grant
Journal:  Mol Cancer Ther       Date:  2002-02       Impact factor: 6.261

2.  Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.

Authors:  M B Thomas; C Koller; Y Yang; Y Shen; S O'Brien; H Kantarjian; J Davis; E Estey
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

3.  Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.

Authors:  S Harvey; R Decker; Y Dai; G Schaefer; L Tang; L Kramer; P Dent; S Grant
Journal:  Clin Cancer Res       Date:  2001-02       Impact factor: 12.531

4.  Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganous superoxide dismutase.

Authors:  Zhu Guo; Gunther H Boekhoudt; Jeremy M Boss
Journal:  J Biol Chem       Date:  2003-04-08       Impact factor: 5.157

5.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.

Authors:  A A Ruefli; M J Ausserlechner; D Bernhard; V R Sutton; K M Tainton; R Kofler; M J Smyth; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

6.  Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

Authors:  J Almenara; R Rosato; S Grant
Journal:  Leukemia       Date:  2002-07       Impact factor: 11.528

7.  Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: role of bcl-2.

Authors:  D W Hedley; E A McCulloch
Journal:  Leukemia       Date:  1996-07       Impact factor: 11.528

8.  The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Authors:  Lisa M Butler; Xianbo Zhou; Wei-Sheng Xu; Howard I Scher; Richard A Rifkind; Paul A Marks; Victoria M Richon
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-20       Impact factor: 11.205

Review 9.  Caspase-2 redux.

Authors:  C M Troy; M L Shelanski
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

10.  Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization.

Authors:  Patrice Lassus; Ximena Opitz-Araya; Yuri Lazebnik
Journal:  Science       Date:  2002-08-23       Impact factor: 47.728

View more
  53 in total

1.  LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

Authors:  Roberto Rosato; Stefanie Hock; Paul Dent; Yun Dai; Steven Grant
Journal:  Leuk Res       Date:  2011-11-08       Impact factor: 3.156

2.  Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.

Authors:  Nilsa Rivera-Del Valle; Tiewei Cheng; Mary E Irwin; Hayley Donnella; Melissa M Singh; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-08       Impact factor: 3.333

3.  Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Dmitry Lembersky; Minkyeong P Son; Elisa Attkisson; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Steven Grant
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

Review 4.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.

Authors:  S Spiegel; S Milstien; S Grant
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

5.  Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC).

Authors:  Preethi G Anantharaju; Bandi Deepa Reddy; Mahesh A Padukudru; Ch M Kumari Chitturi; Manjunath G Vimalambike; SubbaRao V Madhunapantula
Journal:  Cancer Biol Ther       Date:  2017-05-16       Impact factor: 4.742

Review 6.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

7.  Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

Authors:  Margaret A Park; Roland Reinehr; Dieter Häussinger; Christina Voelkel-Johnson; Besim Ogretmen; Adly Yacoub; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

8.  Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.

Authors:  Christina S Baik; Eric H Rubin; Patrick M Forde; Janice M Mehnert; Deborah Collyar; Marcus O Butler; Erica L Dixon; Laura Q M Chow
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

Review 9.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

10.  HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates.

Authors:  Praveen Rajendran; Ariam I Kidane; Tian-Wei Yu; Wan-Mohaiza Dashwood; William H Bisson; Christiane V Löhr; Emily Ho; David E Williams; Roderick H Dashwood
Journal:  Epigenetics       Date:  2013-04-26       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.